Clinical evidence has showed that combining oncolytic viruses with checkpoint inhibitors CTLA-4 in various cancer types, including prostate, and melanoma xenografts, resulted in upregulation of intratumoral T cells and boosting T cell immunity to solid tumors [4,5]. This evidence concerns the gene CTLA4 and melanoma.